UroGen Pharma Announced Topline Data From Phase 3 Trials ATLAS And ENVISION Studying UGN-102 For Intravesical Solution In Patients With Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer; Both Trials Met Primary Endpoints
UroGen Pharma Announced Topline Data From Phase 3 Trials ATLAS And ENVISION Studying UGN-102 For Intravesical Solution In Patients With Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer; Both Trials Met Primary Endpoints
UroGen Pharma 公佈了 ATLAS 和 ENVISION 研究 UGN-102 用於低級、中等風險非肌肉浸潤性膀胱癌患者的膀胱內溶液的 3 期試驗的頭條數據；兩項試驗都達到了主要終點
-- In ATLAS, UGN-102 Demonstrated Superiority to TURBT with a 55% Reduction of Risk for Recurrence, Progression or Death in Patients who Received UGN-102 --
— 在 ATLAS 中，UGN-102 表現出優於 TURBT，接受 UGN-102 治療的患者的復發、進展或死亡風險降低了 55% —
-- ENVISION Showed a Complete Response Rate of 79.2% at 3-Months --
— ENVISION 在 3 個月內的完全回覆率爲 79.2% —
-- Side Effect Profile in ATLAS and ENVISION Consistent with Previous Clinical Trials of UGN-102 --
— ATLAS 和 ENVISION 中的副作用概況與之前的 UGN-102 臨床試驗一致——
-- UroGen Will Review ATLAS and ENVISION Top-line Data Today at 10:00 a.m. Eastern Time --
— UroGen 將於美國東部時間今天上午 10:00 審查 ATLAS 和 ENVISION 的頂級數據 —
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。